Drug recall · October 5, 2022
Budesonide Inhalation Suspension 0.25mg/2mL recall
Why: Lack of Assurance of Sterility
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Budesonide Inhalation Suspension 0.25mg/2mL, For Inhalation Only, Rx Only, 1 envelope x five 2 mL Single Dose Ampules per pouch, Sterile Suspension, Manufactured by: Cipla Ltd., India, Manufactured for Cipla USA Inc., Warren NJ, NDC# 69097-318-86.
- Lots / codes
Lot #s: GA20080, GA20081, GA20094, Exp. 01/2024
- Quantity
- 641,160 ampules
- Company
- Cipla, Warren, NJ
- Distribution
- Nationwide in the USA and Puerto Rico
- Initiated
- September 15, 2022 · Voluntary: Firm initiated
- Classified
- September 27, 2022
- Reported
- October 5, 2022
- Ended
- January 10, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Budesonide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.